NCT00954278View on ClinicalTrials.gov

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 28, 2009

Primary Completion Date

December 23, 2015

Study Completion Date

December 23, 2015

Conditions

Carcinoma, Non Small Cell Lung

Interventions

DRUG

sorafenib

sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days

Trial Locations (1)

53792

University of Wisconsin - Madison, Madison

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT00954278 - Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter